In a letter to FDA Commissioner von Eschenbach, Chairman Waxman requested a briefing on FDA inspections of all facilities owned by the Shanghai Pharmaceutical Group that produce drugs for the United States. The Chinese company is currently under criminal investigation in China for the production of tainted leukemia drugs and manufactures at least one drug for export to the United States.